Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Chemical/toxin · Ischaemia-reperfusion
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 2
2 studies reported at therapy level; 2 evidence entries itemised.
MouseChemical/toxin
Model: Adriamycin (doxorubicin)-induced nephropathy with podocyte injury in mice, with parallel experiments in cultured human podocytes
Leonurine significantly prevented early kidney damage, macrophage infiltration and proteinuria in adriamycin nephropathy, and suppressed podocyte injury and reactive oxygen species production both in vivo and in cultured human podocytes.
Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.
RatIschaemia-reperfusionCerebral (MCAO/stroke)Sprague-DawleyMaleIntraperitoneal7.5 or 15 mg/kg/dayFirst dose 2 h after MCAO surgery
Model: Focal cerebral ischaemia induced by permanent middle cerebral artery occlusion (MCAO)
Leonurine significantly alleviated neurological deficit and decreased brain water content and infarct volume after ischaemic stroke, accompanied by decreased MDA and Bax, increased SOD, CAT, UCP4 and Bcl-2, and restored mitochondrial ultrastructure. Quantitative effect sizes were not reported in th…
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.
